Domann in the News

Our more than thirty year commitment supporting the entrepreneurial spirit continues with our ongoing sponsorship of conferences, symposiums and educational forums focused on bringing emerging growth companies together with investors, venture capitalists, and industry professionals.

You’ll find the latest Domann news below

To receive a list of the Domann Organizations search activity or to contact Domann about a search that you may be considering Please reach out to Jovanna Bost, Chief Business Officer/Partner at

Domann Organization is celebrating 35 years

July 2023

We are pleased to share that the Domann Organization is celebrating 35 years in the retained executive search business serving the Life Sciences.

Thank you to all who have been part of our history improving the lives of many.

We look forward to continuing to build Life Science companies, creating value to our clients, their investors and the candidates we place who excel in their professions.

“the greatest achievement of the human spirit is to live up to one’s opportunities and make the most of one’s resources” Vauvenargues

Founded in San Francisco, 1988, The Domann Organization is pleased to announce that we are entering our 35th year in the Life Sciences retained search business. Domann’s client base is primarily Venture backed Seed, Series A & B start-ups and smaller public Life Science clients who Domann worked with when pre-IPO.

January, 2023

Over the past 24 months we successfully completed key searches for the following private companies:

MBX Biosciences, (Independent Board Member, Chief Medical Officer, Global Vice President Regulatory)

Medikine, (President/Chief Medical Officer/Board Member)

Lengo Therapeutics, (Chief Medical Officer)

Estrigenix Therapeutics, (Executive Chair)

OnLume Surgical, (Chief Executive Officer)

ShouTi, (Senior Vice President, Biology)

Sardocor/Medera Bio (Vice President, Quality Operations, Vice President, Technical Operations)

Recent IPO public companies:

Inozyme Pharma (Senior Vice President, Technical Operations, Senior Vice President, Chief Medical Officer)

Oncolytics Biotech, (Chief Medical Officer, Executive Director, Clinical Operations, 

Executive Director, Translational Sciences, Medical Director, Clinical Development-Oncology)

Why Domann stands apart: Value creation for client, candidate, and investor. Name recognition, experience, knowledge of the Life Sciences community. Transparency, track record, network and trust.

It has been an active 24 months and we are looking forward to continuing building winning Life Science companies which make a major impact on people’s lives.

When considering search…consider Domann, Life Science leadership.

Bill Domann Email: Jovanna Bost Email: 

The Domann Organization celebrates 20 years in San Diego

September 2021

Founded in San Francisco in 1988, Domann opened its San Diego office in 2001 and thanks the companies and individuals in the community who we served and supported.

Actimis Pharmaceuticals
Ambit Biosciences
Ankasa Therapeutics
Archimedes Therapeutics
Celladon Corporation
Crinetics Pharmaceuticals
Digital Gene Technologies
La Jolla Pharmaceuticals
LumMed Corporation
Neurana Pharmaceuticals
Oncolytics Biotech
Ossur America
PRA International
Retrophin, Inc.
Scripps Advance Fund
Target Protein Technologies
Viacyte, Inc.
aFRAXis, Inc.
Angstrom Pharmaceuticals
Aristea Therapeutics
Arcturus Therapeutics
COI Pharmaceuticals
Dart Neurosciences
Lengo Therapeutics
Novalar Pharmaceuticals
OncoStar Pharmaceuticals
Plexxus Vaccines
Prometheus Laboratories
Sardocor Corporation
Synthorx, Inc.
Traversa Therapeutics
ZyGem Corporation

The Domann Organization-Domann the Board Room Inc. Midwest Practice 2010 to Present

July 2020

The Domann Organization, Domann-The Board Room Inc. established a presence in the Midwest in 2010 and is celebrating 10 years representing the Life Science Community. Bill Domann Founder & CEO was raised and educated in Wisconsin and founded the Domann Organization in San Francisco, 1988.
The platform for the Midwest practice is to recruit tenured leadership who have achieved “C” Suite status in the Life Sciences with roots in the Midwest, either having lived, educated or worked in the region now living on the coasts.

Domann also makes introductions to the Investment Community we have built and worked for over the past 20 plus years. Domann sponsors and supports key Investment Conferences in the region. Wisconsin Technology Council Early Stage Symposium & Wisconsin Entrepreneur’s Conference, Invest Midwest Venture Capital Forum, Michigan Growth Capital Symposium, MidAmerica Healthcare Venture Forum, BioForward-Bioscience Vision Summit, MRUN, Invest Midwest and BioCrossroads Indiana Life Sciences Summit. Domann is a member of BioForward, Bill served a three year term 2013 – 2016, MICHBIO and iBIO. Bill serves an Advisor to the Badger Fund and AmebaGone.

85% of Domann’s Client base is Seed, Series A & B Life Science start-ups.

Domann Midwest Search Activity

FluGen, Inc. Chairman of the Board
Aratana Therapeutics Independent Board Member
Kempharm Independent Board Member
Naurex Chief Executive Officer & Independent Board Member
OnLume Surgical, Inc. Chief Executive Officer
Cellectar Biosciences Chief Executive Officer
Deltanoid Pharma Chief Executive Officer
Gemphire Therapeutics Chief Executive Officer/ Board Member
Gregor Diagnostics Scientific Advisory Board Member (2)
ENDECE Neural, LLC Strategic Advisor-Business Development
UW Health-Isthmus Project Chief Innovation Officer
MBX Biosciences Chief Medical Officer
AIQ Solutions Vice President, Business Development
Kempharm Chief Operating & Financial Officer
Swift Biosciences Chief Technical Officer/ Chief Executive Officer

For additional information or to discuss search needs please contact Bill Domann @ or Jovanna Bost @